Consolidated Financial Statements
(Expressed in thousands of Canadian dollars)

CARDIOME PHARMA CORP.

Periods ended March 31, 2009 and 2008
(Unaudited)

CARDIOME PHARMA CORP.

Consolidated Balance Sheets
(Expressed in thousands of Canadian dollars)

	As at	
	March 31, 2009 (Unaudited)	December 31, 2008 (Restated-note 2(a))
Assets		
Current assets:		
Cash and cash equivalents	$ 24,515	$ 37,142
Accounts receivable	844	595
Prepaid expenses and other assets	1,840	1,324
	27,199	39,061
Property and equipment	3,447	3,725
Intangible assets	17,979	18,535
	$ 48,625	$ 61,321
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable and accrued liabilities	$ 10,464	$ 11,503
Current portion of deferred leasehold inducement	206	206
	10,670	11,709
Deferred leasehold inducement	842	893
Shareholders' equity:		
Common shares	327,986	327,986
Preferred shares (note 4(a))	25,181	25,181
Contributed surplus	25,387	24,955
Deficit	(341,441)	(329,403)
	37,113	48,719
	$ 48,625	$ 61,321

See accompanying notes to the consolidated financial statements.

Approved on behalf of the Board:

/s/ Peter W. Roberts
Director

/s/ Harold H. Shlevin
Director

CARDIOME PHARMA CORP.

Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(Expressed in thousands of Canadian dollars except share and per share amounts)

	Three months ended	
	March 31, 2009	March 31, 2008 (Restated-note 2(a))
Revenue:		
Licensing fees	$ -	$ 224
Research collaborative fees	274	232
	274	456
Expenses:		
Research and development	7,715	18,212
General and administration	4,137	4,112
Amortization	832	1,011
	12,684	23,335
Operating loss	(12,410)	(22,879)
Other income:		
Interest and other income	31	326
Foreign exchange gain	341	310
	372	636
Net loss for the period	(12,038)	(22,243)
Other comprehensive income, net of income taxes:		
Reclassification adjustment for realized loss included in net loss	-	10
Comprehensive loss for the period	$ (12,038)	$ (22,233)
Basic and diluted loss per common share[(1)]	$ (0.19)	$ (0.35)
Weighted average number of common shares outstanding	63,762,296	63,727,290

(1) Basic and diluted loss per common share based on the weighted average number of common shares outstanding during the period.

See accompanying notes to the consolidated financial statements.

CARDIOME PHARMA CORP.

Consolidated Statements of Shareholders' Equity
(Unaudited)
(Expressed in thousands of Canadian dollars)

	Three months ended	
	March 31, 2009	March 31, 2008 (Restated-note 2(a))
Common shares:		
Balance, beginning and end of period	$ 327,986	$ 327,835
Preferred shares:		
Balance, beginning and end of period	25,181	-
Contributed surplus:		
Balance, beginning of period	24,955	21,927
Stock option expense recognized	432	1,014
Balance, end of period	25,387	22,941
Deficit:		
Balance, beginning of period	(329,403)	(269,041)
Net loss for the period	(12,038)	(22,243)
Balance, end of period	(341,441)	(291,284)
Accumulated other comprehensive income (loss):		
Balance, beginning of period	-	(10)
Other comprehensive income (loss) for the period	-	10
Balance, end of period	-	-
Total shareholders' equity	$ 37,113	$ 59,492

See accompanying notes to the consolidated financial statements.

CARDIOME PHARMA CORP.

Consolidated Statements of Cash Flows
(Unaudited)
(Expressed in thousands of Canadian dollars)

	Three months ended	
	March 31, 2009	March 31, 2008 (Restated-note 2(a))
Cash provided by (used in):		
Operations:		
Net loss for the period	$ (12,038)	$ (22,243)
Add items not affecting cash:		
Amortization	832	1,011
Stock-based compensation	432	1,014
Deferred leasehold inducement	(51)	(13)
Foreign exchange gain	(192)	(1,219)
Write off of property and equipment	3	-
Adjustment to reconcile net loss to net cash used in operating activities:		
Accounts receivable	(249)	674
Prepaid expenses	(516)	(1,161)
Accounts payable and accrued liabilities	(1,039)	2,843
Deferred revenue	-	(224)
	(12,818)	(19,318)
Investments:		
Purchase of property and equipment	(1)	(262)
Sale of short-term investments	-	157
	(1)	(105)
Foreign exchange gain on cash and cash equivalents held in foreign currencies	192	2,165
Decrease in cash and cash equivalents during the period	(12,627)	(17,258)
Cash and cash equivalents, beginning of period	37,142	67,988
Cash and cash equivalents, end of period	$ 24,515	$ 50,730
Supplemental cash flow information:		
Interest paid	$ 4	$ 4
Interest received	32	446

See accompanying notes to the consolidated financial statements.

1. Basis of presentation:

These unaudited interim consolidated financial statements have been prepared by management in accordance with Canadian generally accepted accounting principles (Canadian GAAP) on a basis consistent with Cardiome Pharma Corp's (the Company) annual audited consolidated financial statements for the year ended December 31, 2008, except as described in note 2 below. These unaudited interim consolidated financial statements do not include all note disclosures required by Canadian GAAP for annual financial statements, and therefore should be read in conjunction with the annual audited consolidated financial statements for the year ended December 31, 2008 filed with the appropriate securities commissions. The results of operations for the three-month periods ended March 31, 2009 and 2008 are not necessarily indicative of the results for the full year.

The Company has financed its cash requirements primarily from share issuances, payments from research collaborators and licensing fees. The Company's ability to realize the carrying value of its assets is dependent on successfully bringing its technologies to market and achieving future profitable operations, the outcome of which cannot be predicted at this time.

2. Changes in accounting policies:

(a) Goodwill and Intangible Assets

On January 1, 2009, the Company retrospectively adopted the Canadian Institute of Chartered Accountants (CICA) Handbook Section 3064, *Goodwill and Intangible Assets,* which replaced Section 3062, *Goodwill and Other Intangible Assets,* and Section 3450, *Research and Development Costs.* The new standard, which applies to fiscal years beginning on or after October 1, 2008, clarifies the recognition of intangible assets, including internally generated assets. The standard reinforces the principle-based approach to the recognition of assets only in accordance with the definition of an asset and the criteria for asset recognition. The standard also provides guidance on the recognition and measurement of internally generated assets, including assets developed from research and development activities, ensuring consistent treatment of all intangible assets, whether separately acquired or internally developed.

Upon adoption of this new standard, patent costs previously capitalized did not meet the new criteria for capitalization. The impact on the financial position of the Company was a decrease in intangible assets and an increase in deficit at December 31, 2008 and 2007 of $1,816 and $1,974, respectively, relating to patent costs capitalized in prior periods. The impact on the consolidated statements of operations and comprehensive loss for the three months ended March 31, 2008, was an increase in research and development costs of $144 and a decrease in amortization of $80, resulting in an overall increase in net loss of $64. The basic and diluted loss per common share remained unaffected as a result of the retrospective restatement.

2. Changes in accounting policies (continued):

(b) Credit Risk and the Fair Value of Financial Assets and Financial Liabilities

On January 1, 2009, the Company adopted the Emerging Issues Committee (EIC) Abstract No. 173, *Credit Risk and the Fair Value of Financial Assets and Financial Liabilities* (EIC – 173). EIC – 173 requires that an entity's own credit risk and the credit risk of the counterparty should be taken into account in determining the fair value of financial assets and financial liabilities, including derivative instruments. The accounting treatment of this Abstract is to be applied retrospectively without restatement of prior periods to all financial assets and liabilities measured at fair value in interim and annual financial statements for periods ending on or after January 20, 2009. The adoption of this Abstract did not have an impact on the Company's consolidated financial statements.

3. Future changes in accounting policies:

(a) International Financial Reporting Standards

On February 13, 2008, the Accounting Standards Board confirmed that the use of International Financial Reporting Standards (IFRS) will be required, for fiscal years beginning on or after January 1, 2011, for publicly accountable profit-oriented enterprises. After that date, IFRS will replace Canadian GAAP for those enterprises. The Company is currently assessing the impact of these new standards on its consolidated financial statements.

(b) Business Combinations

In January 2009, the CICA issued Handbook Section 1582, *Business Combinations*, which replaced Section 1581, *Business Combinations.* The new standard adopts relevant parts of IFRS 3, *Business Combinations,* in establishing standards for the accounting for a business combination. The standard applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after January 1, 2011. Earlier application is permitted. The Company does not expect the adoption of the standard to have a material impact on its consolidated financial statements.

(c) Consolidated Financial Statements and Non-Controlling Interests

In January 2009, the CICA issued Handbook Section 1601, *Consolidated Financial Statements*, and Section 1602, *Non-Controlling Interests,* which together replaced Section 1600, *Consolidated Financial Statements.* The new standards establish accounting for a non-controlling interest in a subsidiary in consolidated financial statements subsequent to a business combination. The new standards apply to interim and annual consolidated financial statements relating to fiscal years beginning on or after January 1, 2011. Earlier adoption is permitted as of the beginning of a fiscal year. The Company does not expect the adoption of the standard to have a material impact on its consolidated financial statements.

(Expressed in thousands of Canadian dollars except share and per share amounts and where otherwise indicated)

4. Share capital:

(a) Issuance of preferred shares:

On October 23, 2008, in connection with the issuance of 2,272,727 preferred shares, the Company filed a Canadian prospectus and related U.S. registration statement (the "registration statement") to register the shares issuable upon conversion of the Series A preferred shares. The registration statement became effective November 6, 2008. If the effectiveness of the registration statement is not maintained, the Company is subject to a registration payment arrangement under which it is required to pay an amount equal to 1.5% of the purchase price of the preferred shares on the thirtieth day following the failure to maintain the effectiveness requirement and for each thirtieth day thereafter until the earlier of reobtaining effectiveness or July 25, 2009. As at March 31, 2009, the maximum amount that the Company could be required to pay if it fails to maintain an effective registration statement is U.S.$1,450. The Company has not recorded a liability related to the registration payment arrangement at March 31, 2009, because it does not believe that payment is probable.

(b) Stock options:

Details of the stock option transactions for the three months ended March 31, 2009 are summarized as follows:

	Number of stock options outstanding	Weighted average exercise price ($)
Balance, December 31, 2008	4,828,562	8.30
Options forfeited	(18,500)	11.16
Balance, March 31, 2009	4,810,062	8.29

(Expressed in thousands of Canadian dollars except share and per share amounts and where otherwise indicated)

4. Share capital (continued):

(b) Stock options (continued):

At March 31, 2009, stock options to executive officers and directors, employees and consultants were outstanding as follows:

	Options outstanding			Options exercisable	
Range of exercise prices	Number of common shares issuable	Weighted average remaining contractual life (years)	Weighted average exercise price($)	Number of common shares issuable	Weighted average exercise price ($)
$3.32 to $5.54	1,205,200	0.18	3.70	1,205,200	3.70
$6.06 to $8.95	1,647,353	1.77	7.78	1,594,853	7.76
$8.98 to $11.15	997,767	3.66	10.16	504,360	10.21
$11.26 to $14.59	959,742	3.70	12.99	686,626	13.11
	4,810,062	2.15	8.29	3,991,039	7.76

(c) Stock-based compensation:

The estimated fair value of options granted from December 1, 2002 to officers, directors, employees and consultants is amortized over the vesting period. Compensation expense is recorded in research and development expenses and general and administration expenses as follows:

	For the Three Months Ended March 31	
	2009	2008
Research and development	$ 134	$ 399
General and administration	298	615
Total	$ 432	$ 1,014

(Expressed in thousands of Canadian dollars except share and per share amounts and where otherwise indicated)

4. Share capital (continued):

(c) Stock-based compensation (continued):

The Company did not grant any stock options during the three months ended March 31, 2009. The weighted average fair value of stock options granted during the three months ended March 31, 2008 was $3.61 per option. The estimated fair value of the stock options granted was determined using the Black-Scholes option pricing model with the following weighted-average assumptions:

	For the Three Months Ended March 31	
	2009	2008
Dividend yield	-	0%
Expected volatility	-	47.2%
Risk-free interest rate	-	3.4%
Expected average life of the options	-	4.5 years

5. Related party transactions:

The Company has incurred expenses for services provided by a law firm in which an officer is a partner. The amounts charged are recorded at their exchange amounts and are subject to normal trade terms. For the three months ended March 31, 2009, the Company has incurred legal fees of $292 for services provided by the law firm relating to general corporate matters and review of partnership opportunities (three months ended March 31, 2008 - $252). Included in accounts payable and accrued liabilities at March 31, 2009 is an amount of $211 (December 31, 2008 - $150) owing to the legal firm.

6. Subsequent event:

On April 8, 2009, the Company entered into a collaboration and license agreement with Merck & Co., Inc. (Merck) for the development and commercialization of vernakalant. Pursuant to this agreement, the Company has granted Merck exclusive global rights to the oral formulation of vernakalant (vernakalant (oral)), and has granted a Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, exclusive rights outside of the United States, Canada and Mexico to the intravenous (iv) formulation of vernakalant (vernakalant (iv)). This agreement is subject to receipt of regulatory approval under anti-competition legislation in the United States, at which time the principal terms of the agreement will become effective. The Company's agreement with Astellas Pharma U.S., Inc. for vernakalant (iv) in the United States, Canada and Mexico is unaffected by this agreement.

Under the terms of the agreement, Merck has agreed to pay the Company an up-front payment of U.S.$60 million, milestone payments of up to U.S.$200 million based on achievement of certain development and approval milestones associated with vernakalant products, including a total of

6. Subsequent event (continued):

U.S.$35 million for initiation of a planned Phase 3 program for vernakalant (oral) and submission for regulatory approval in Europe of vernakalant (iv), and up to U.S.$100 million for milestones associated with approvals in other subsequent indications of both the intravenous and oral formulations. In addition, the Company will receive tiered royalty payments on sales of any approved products and have the potential to receive milestone payments of up to U.S.$340 million based on achievement of significant sales thresholds. Merck has also granted the Company a secured, interest-bearing credit facility of up to U.S.$100 million that can be accessed in tranches over several years commencing in 2010. The Company has also retained an option to co-promote vernakalant (oral) with Merck through a hospital-based sales force in the United States. Merck will be responsible for all future costs associated with the development, manufacturing and commercialization of these candidates.